Reports Q4 revenue $17.3M, consensus $17.1M. “Our performance in 2025 was transformative, demonstrated by 400% year-over-year clinical volume growth and pivotal Medicare coverage for breast and lung cancer,” said Chris Hall, Chief Executive Officer and President. “We enter 2026 with a fortified balance sheet of approximately $240 million in cash, which allows us to expand our investments in our ‘Win-in-MRD’ strategy. While we are in the early stages of reimbursement, we are driving volume now to secure long-term market leadership. We expect 2026 to be a year of rapid commercial expansion, with clinical revenue projected to grow approximately five-fold as we operationalize our recent coverage wins.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSNL:
- Expanding Reimbursement and Market Reach Underpin Buy Rating and $13 Target on Personalis
- Personalis’ MRD test receives Medicare coverage in lung cancer surveillance
- Personalis announces publication of new study on NeXT Personal
- Personalis price target raised to $13 from $12 at Guggenheim
- Cathie Wood Doubles Down on High-Potential Biotech Plays